Jun 28, 2022 01:50PM
Jun 24, 2022 02:41PM
May 26, 2022 05:30PM
May 19, 2022 04:30PM
May 17, 2022 07:00AM
Mar 31, 2022 05:27PM
Mar 23, 2022 07:00AM 4D pharma Announces Positive Interim Results from the Phase I/II Study of the Combination of MRx0518 and KEYTRUDA® (pembrolizumab) for the Treatment of Renal Cell Carcinoma
Feb 23, 2022 07:00AM
Feb 22, 2022 07:00AM
Jan 27, 2022 07:00AM
Jan 20, 2022 07:00AM
Jan 5, 2022 07:00AM
Jan 3, 2022 07:00AM
Dec 9, 2021 07:00AM 4D pharma Presents Microbiome Analyses from Phase II Clinical Trial of Blautix® for IBS-C and IBS-D at Gastro 2021
Nov 11, 2021 07:00AM
Oct 12, 2021 07:00AM
Sep 15, 2021 07:00AM
Sep 9, 2021 07:00AM
Aug 2, 2021 07:00AM
Jul 29, 2021 07:00AM
Jul 26, 2021 08:00AM 4D pharma Announces Passing of Chief Financial Officer John Beck
Jul 6, 2021 07:09AM
Jul 6, 2021 07:00AM
Jun 29, 2021 07:00AM
Jun 22, 2021 07:00AM
Jun 4, 2021 07:00AM
May 24, 2021 07:05AM
May 24, 2021 07:00AM 4D pharma Presents Additional Positive Results of Phase II Study of Blautix® for the Treatment of Irritable Bowel Syndrome
May 17, 2021 07:00AM
Apr 19, 2021 07:25AM
Apr 19, 2021 07:00AM
Mar 22, 2021 03:00AM
Mar 22, 2021 03:00AM
Mar 17, 2021 09:23AM
Mar 3, 2021 07:00AM 4D Pharma to Present at Upcoming Investor Conferences in March
Mar 1, 2021 07:05AM
Mar 1, 2021 07:00AM
Feb 26, 2021 02:00AM
Feb 16, 2021 07:00AM
Feb 8, 2021 07:00AM
Feb 3, 2021 07:00AM
Jan 21, 2021 07:00AM 4D pharma to Participate in 5th Microbiome Movement Drug Development Summit Europe
Dec 21, 2020 08:00AM
Nov 27, 2020 08:00AM
Nov 9, 2020 08:00AM
Nov 5, 2020 09:00AM
Oct 22, 2020 02:00AM
Mar 17, 2020 03:00AM
Jan 6, 2020 02:00AM Clinical Update - 4D Announce New Study of MRx0518 in Pancreatic Cancer
Nov 6, 2019 02:00AM

324,250 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All